Peptide bioregulators: delivery and efficacy
Erichev VP, Lovpache DN, Yaremenko TV · 2020 · Vestn Oftalmol 136(2):56-62. PMID 32366071
What does this source report?
Compares administration routes of Retinalamin. Visual acuity did not change significantly; retinal-sensitivity results varied by disease stage and follow-up.
- Population and setting
- Open-angle glaucoma; 498 patients (eyes), as worded in the abstract
- Evidence type
- Human comparative study
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- All compared groups received active preparation; this does not isolate benefit versus no Retinalamin.
- Patient/eye unit wording should be checked in full text. Findings do not establish benefit for Normophthal.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-29. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Erichev VP, Lovpache DN, Yaremenko TV. Peptide bioregulators: delivery and efficacy Vestn Oftalmol 136(2):56-62. PMID 32366071 2020.
Molekul research summary: https://molekul.io/research/bio-32366071. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry